TECHNICAL DATA SHEET

CyFlow™ CD263 Azide Free
Anti-Hu; Clone TRAIL-R3-02

REF **AE050786**

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD263
Alternative Names	TRAILR3, DCR1, LIT, TRID, TNFRSF10c
Clone	TRAIL-R3-02
Clonality	monoclonal
Format	Azide Free
Host / Isotype	Mouse / IgG1
Species Reactivity	Human
Negative Species Reactivity	—
Quantity [Concentration]	0.1 mg [1 mg/ml]
Immunogen	TRAIL-R3 (aa 1-280) - hIgGhc fusion protein

Specificity

The mouse monoclonal antibody TRAIL-R3-02 recognizes CD263 (TRAIL-R3) antigen, a 35 kDa GPI-anchored extracellular membrane protein expressed mainly on neutrophils.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry

Storage Buffer

The reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

CD263 (TRAIL-R3, TR3, DcR1, LIT, TRID), expressed mainly on neutrophils, belongs to receptors of TRAIL, a TNF-like membrane cytotoxic protein that induces apoptosis in many tumor cells, but not in normal cells. TRAIL-R3, however, is a GPI-anchored protein that lacks cytoplasmic death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by competing for binding of TRAIL with death receptor 5 (DR5).

References

- Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA. 2005 Dec 13; 102(50):18099-104. < PMID: 16319225 >
- Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S: Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25; 5(1):54. < PMID: 18518976 >
- Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct; 26(19):7046-55. < PMID: 16980609 >
- Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007; 13(4):290-4. < PMID: 18158563 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

• Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling. Int J Biochem Cell Biol. 2007; 39(7-8):1462-75. < PMID: 17403612 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com